TheEdgeResearch
Home / Stocks / SUPN

Supernus Pharmaceuticals, Inc. (SUPN)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$46.94 ▼ -1.94%
Market Cap
$2.72B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.54
52-Wk Range
32.51-59.68
CEO
Jack A. Khattar
Country
US
Currency
USD

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor…

Open full interactive analysis & DCF →